Cancer Research Consortium of West Michigan
P: 616.391.1230 | 800.336.6299 | www.crcwm.org

FAST FACTS

URCC 19075: MULTI-CENTER RANDOMIZED CONTROLLED PHASE II TRIAL OF EXERCISE TO TREAT CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)

ELIGIBILITY CRITERIA

Inclusion Criteria (patients must…)

1. **Have a diagnosis of cancer.**
2. **Have received an infusion of neurotoxic chemotherapy within the past nine months (could still be on chemotherapy or have already completed chemotherapy; i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy).**
3. **Report one or more symptoms of CIPN at a level of ≥4 on the CIPN symptom inventory on the Screening Form.**
4. **Have an ECOG Performance Status 0-1.**
5. **Have at least six months life expectancy.**
6. **Be at least 18 years of age.**
7. **Be able to read and understand English.**
8. **Be able to provide written informed consent.**

Exclusion Criteria (patients must not…)

1. **Have physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in a low to moderate intensity home-based walking and progressive**

resistance exercise program, according to the patient's physician (e.g., oncologist, primary care) or physician's designee.

2. **Be identified as in the active or maintenance stage of exercise behavior per the Exercise Stages of Change Question on the Screening Form.**

3. **Have planned surgery or radiation treatment during the course of the study (hormonal and biologic therapy is allowed).**

Study schema



CIPN = chemotherapy-induced peripheral neuropathy. MRI = magnetic resonance imaging. The total study duration is approximately 7-8 weeks pre- and post-intervention assessments may take 1-2 weeks each surrounding the 6-week intervention. Note: the brain MRI scans are optional for affiliate sites and participants.